Santiago Acero-Bedoya, PhD (he/him)

Assoc @ RA Cap | ex @Pillar_VC & @CivilizationVC | Postdoc @nygenome | PhD @UChicago | @NCICancerBio F99/K00 Fellow | @NSFGRFP | @NucleateHQ | Immigrant 🇨🇴

[Santiago Acero-Bedoya, PhD (he/him) @acerobed]

Still trying to wrap my mind around the fact that I have been awarded the @NCICancerBio F99/K00. I can’t shake the feeling that someone like me (Latinx immigrant) has earned such an honor, but I know it’s not just mine. Eternally thankful to everyone who has taken a chance on me.

[Denis Wirtz @deniswirtz]

Here is our updated database of grants for early careers researchers in all fields.

It goes way beyond traditional NIH and NSF funding opportunities. We list 428 types of grants.

Download it here: https://t.co/RGXGrdp2uf

[Prof. Michael Lin @MichaelLinLab]

Today I'd like to honor the memory of my mentor and friend, Roger Tsien, born 1952 February 1. Today would have been Roger's 74th birthday.

Most know Roger for his 2008 Chemistry Nobel Prize with Shimomura and Chalfie. Roger made GFP into the versatile imaging method it is now.

[Journal of Clinical Investigation @jclinicalinvest]

Fanning the flames: IFN-γ fuels CAR-T inflammation and cytopenia: https://t.co/cvWKMouoEn

A Commentary by Stefanie R. Bailey & Marcela V. Maus @MarcelaMaus @harvardmed on Payal Goala et al.: https://t.co/XN7ZFmmwLX

[No Patient Left Behind @NPLB_org]

🔬 Want to understand how drugs are developed and made affordable?

Join NPLB Biotech Fellows → live sessions, real-world projects, and a global network spanning every top 50+ U.S. university.

👉 Apply now to join us this spring: https://t.co/Cj1nCPai68

#NPLBFellowship #BiotechSocialContract #AffordableInnovation #Biotech

[Peter Kolchinsky @PeterKolchinsky]

Raj and I just dropped the 2026 Semper Maior report. 20 years of M&A lessons + a massive deep dive into deal data since 2019. Lot's of hard-earned lessons in here.

Read it on your way to JPM before your strategic meetings. Good luck out there!

#JPM2026

[Peter Kolchinsky @PeterKolchinsky]

We analyzed impact of CMS's "experimental" GLOBE/GUARD policies to cap US prices at what other countries pay (answer: backfire). Note: doesn't lower what patients pay... that's a function what insurance gets away with charging sick people out of pocket. https://t.co/tdV9MOpvDN

[Lior Pachter @lpachter]

Single-cell genomics finally makes it into the clinic. “Can you show me on the UMAP where it hurts?”

[Matthew Herper @matthewherper]

Miriam Merad’s 20-year quest to understand one cell is starting to rewrite the rules of cancer immunotherapy https://t.co/cFYCXoyJ1w

[Samuel Hume @DrSamuelBHume]

How do the 3 longest-living vertebrates live so long?

The Greenland shark modifies p53 and reduces protein stress

The bowhead whale boosts DNA repair

And the rougheye rockfish alters IGF signalling and controls inflammation

[Bruce Booth @LifeSciVC]

Drug spending isn't the driver of increasing healthcare costs in any OECD country. Drug spend grew slowly for 25 years (yellow line), while overall healthcare spending outpaces it (blue line).

New IQVIA report: https://t.co/eCbEGdVBfe

[Santiago Acero-Bedoya, PhD (he/him) @acerobed]

@rosslevinemd Congrats Ross!! So well deserved! Smart and empathetic. MSK is in great hands.

[Prof. Nikolai Slavov @slavov_n]

bioRxiv has a dedicated section for negative results.

Use it.

Share negative results.
Your colleagues will appreciate it.

[Jennifer Guerriero, PhD @JennGuerriero]

PSA: Stop calling macrophages in tissue M1 or M2. These are not states that exist in biology. The only use of M1 is a macrophage cultured ex vivo with LPS and IFNg; and for M2: IL-4/13/10. Macrophages in tissues are highly complex and diverse and do not resemble either of the aforementioned M1/M2 states. M1/M2 language causes confusion and sets the field back. Refer to your macrophages by the molecules they express and the cytokines they make.

[No Patient Left Behind @NPLB_org]

🧠 Today is #WorldBrainDay.

Over 8M Americans live with neurodegenerative diseases like Alzheimer’s, Huntington’s, and ALS.

#Biotech teams are working on better treatments. If you invest or pay premiums, you may already be helping.

🎥Watch here:

[No Patient Left Behind @NPLB_org]

3.8 million Americans are living with breast cancer.
1 in 8 women will be diagnosed.

#Biotech startups are developing treatments, and if you pay insurance or invest, you may be helping.

🔗 https://t.co/pigLD3JS69

#CommunityQuest #BreastCancer #FixInsurance #ProtectInnovation

[No Patient Left Behind @NPLB_org]

Millions suffer from rheumatoid arthritis.

Biotech is working on cures, but patients still face high out-of-pocket costs.

If you're saving for retirement, you're likely helping fund this research.

Let’s #FixInsurance and #protectUSinnovation during #ArthritisAwarenessMonth.

🎥 https://t.co/LJnrvOIUSA

#ArthritisAwareness

[No Patient Left Behind @NPLB_org]

100K people live with #CysticFibrosis. New treatments offer hope, but not for all.

Meet biotech innovators working toward a cure—and hear how we support their mission.

Price controls risk progress. Patients need access, not high OOP costs.

#CF #biotech #CFAwarenessMonth

[No Patient Left Behind @NPLB_org]

🎥 New video: Meet biotech innovators working to cure ovarian cancer.

By paying your insurance premiums—and saving for retirement—you help efforts like these to vanquish many diseases.

Price controls would kill this progress. Insurance reform—not R&D cuts—is the solution.

[No Patient Left Behind @NPLB_org]

3 million Americans are diagnosed with skin cancer each year.

Our new Community Quest video highlights biotech innovators working on new treatments.

Hear from them why we need to #FixInsurance so that patients can access their prescribed medicines at low out-of-pocket costs.

[No Patient Left Behind @NPLB_org]

Nearly a million Americans are living with multiple sclerosis.

Meet some of the biotech innovators racing to develop breakthrough treatments for patients and their families still waiting for a cure.

Together, we can create a future without MS.